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Impact of plasma potassium normalization
on short-term mortality in patients with
hypertension and hypokalemia or low
normal potassium
Maria Lukács Krogager1* , Peter Søgaard1, Christian Torp-Pedersen2, Henrik Bøggild3,4, Christina Ji-Young Lee2,5,
Anders Bonde5, Jesper Q. Thomassen6, Gunnar Gislason7,8,9, Manan Pareek2,10,11 and Kristian Kragholm1,4,12
Abstract
Background: Hypokalemia is common in patients treated with antihypertensive drugs, but the impact of correcting
hypokalemia is insufficiently studied. We examined the consequences of hypokalemia and borderline hypokalemia
correction in patients with hypertension.
Methods: We identified 8976 patients with hypertension and plasma potassium concentrations ≤3.7 mmol/L within
100 days from combination antihypertensive therapy initiation. The first measurement between 6 and 100 days after
the episode with potassium ≤3.7 mmol/L was retained. We investigated all-cause and cardiovascular mortality
within 60-days from the second potassium measurement using Cox regression. Mortality was examined for seven
predefined potassium intervals derived from the second measurement: 1.5–2.9 mmol/L (n = 271), 3.0–3.4 mmol/L
(n = 1341), 3.5–3.7 (n = 1982) mmol/L, 3.8–4.0 mmol/L (n = 2398, reference), 4.1–4.6 mmol/L (n = 2498), 4.7–5.0 mmol/
L (n = 352) and 5.1–7.1 mmol/L (n = 134).
Results: Multivariable analysis showed that potassium concentrations 1.5–2.9 mmol/L, 3.0–3.4 mmol/L, 4.7–5.0
mmol/L and 5.1–7.1 mmol/L were associated with increased all-cause mortality (HR 2.39, 95% CI 1.66–3.43; HR 1.36,
95% CI 1.04–1.78; HR 2.36, 95% CI 1.68–3.30 and HR 2.62, 95% CI 1.73–3.98, respectively). Potassium levels <3.0
and > 4.6 mmol/L were associated with increased cardiovascular mortality. The adjusted standardized 60-day
mortality risks in the seven strata were: 11.7% (95% CI 8.3–15.0%), 7.1% (95% CI 5.8–8.5%), 6.4% (95% CI 5.3–7.5%),
5.4% (4.5–6.3%), 6.3% (5.4–7.2%), 11.6% (95% CI 8.7–14.6%) and 12.6% (95% CI 8.2–16.9%), respectively.
Conclusions: Persistent hypokalemia was frequent and associated with increased all-cause and cardiovascular
mortality. Increase in potassium to levels > 4.6 mmol/L in patients with initial hypokalemia or low normal potassium
was associated with increased all-cause and cardiovascular mortality.
Keywords: Hypokalemia, Borderline hypokalemia, Hypokalemia correction, Mortality, Low potassium.
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Novelty and Significance
What is new?
 Correcting plasma potassium concentrations ≤3.7
mmol/L to levels between 3.5–4.6 mmol/L was
associated with improved short-term prognosis
What is relevant?
 Increased mortality risk was observed in patients
who initially had borderline hypokalemia, partly
because they developed hypokalemia. This
emphasizes that potassium supplementation might
be relevant in patients with low normal potassium
concentrations
 Correcting hypokalemia and borderline hypokalemia
shortly was associated with good prognosis
 Low potassium concentrations have previously been
associated with arrhythmogenesis and increased
mortality risk in patients with hypertension.
Summary
In this register based study we investigated the impact
of correcting hypokalemia and borderline hypokalemia
on 60-day mortality among 8976 patients treated with
combination antihypertensive therapy. We observed
that: (1) persistent hypokalemia was common and asso-
ciated with increased all-cause and cardiovascular mor-
tality; (2) Increase in potassium to levels > 4.6 mmol/L in
patients with initial hypokalemia or low normal potas-
sium was associated with increased all-cause and cardio-
vascular mortality; (3) Among patients with borderline
hypokalemia initially, development of hypokalemia or
hyperkalemia was associated with increased mortality
risk; (4) Correcting hypokalemia associated with in-
creased survival.
Background
Several common clinical conditions and drugs are
known to cause or precipitate hypokalemia [1]. Among
patients with hypertension, thiazides are the antihyper-
tensive drugs most frequently associated with hypokal-
emia [2–4].
We recently demonstrated a U-shaped relationship be-
tween potassium levels and mortality among patients
with hypertension. We observed an increased mortality
risk even in patients with low and high normal serum
potassium concentrations, suggesting a narrower than
previously thought normal interval for potassium of 4.1–
4.7 mmol/L. [5] However, at present there is no evidence
regarding the consequences of potassium normalization
in patients with hypertension and hypokalemia. There-
fore, it is essential to examine how correction and even
overcorrection of hypokalemia affect prognosis in pa-
tients with hypertension.
Using Danish national registers, we investigated the
60-day mortality among patients with hypertension and
hypokalemia or low normal potassium concentrations,
according to their subsequent plasma potassium concen-
trations measured within 6–100 days following the initial
episode with low potassium levels.
Methods
Data sources
In Denmark, a unique and personal identification num-
ber is allocated to all individuals at the time of birth or
immigration. This unique identifier allows linkage of
health and administrative data at the individual level [6]
and ensures nearly complete follow-up. We used anon-
ymized data from five different registers made available
by Statistics Denmark after central encryption of the
unique identifiers [7]. An overview of the registers used
in this study is available in Supplementary Table S1. In
Denmark, register-based studies using anonymized data
provided by Statistics Denmark are not warranted ap-
proval from the ethics committee.
Study population
We defined hypertension as redemption of minimum
two antihypertensive agents in two consecutive quarters.
This definition has previously been validated [8]. Pa-
tients entered the present study in the second quarter,
referred to as the date of hypertension. An overview of
the Anatomical Therapeutic Chemical Classification
System (ATC) codes used to identify patients with
hypertension is available in Supplementary Table S2. We
required a plasma potassium measurement ≤3.7 mmol/L
within 100 days from the date of hypertension for inclu-
sion. The first measurement within this time interval
was retained and referred to as the first potassium meas-
urement (K1). The second potassium measurement (K2)
was identified in the interval 6–100 days from K1 and
the first draw within this timeframe was retained. We
did not include potassium concentrations within 1–5
days from K1 as, potassium disarrays are usually cor-
rected within a few days, regardless of the strategies ap-
plied. Patients below 18 years of age were excluded from
the study. Supplementary Figure S1 illustrates the popu-
lation flowchart.
Comorbidities and medication
We identified comorbidities and medications regarded
as confounders when studying the association between
changes in potassium levels and short-term mortality.
The following comorbidities dated up to 5 years before
the index date (K2 date) were identified: hospitalization
for heart failure, ischemic heart disease, stroke, chronic
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obstructive pulmonary disease, chronic liver disease, dia-
betes mellitus, inflammatory bowel disease and malig-
nancy. Furthermore, patients with a past history of
primary adrenal insufficiency, primary hyperaldosteron-
ism, and diabetes insipidus were excluded. The Inter-
national Classification of Disease (ICD) codes used to
identify above-mentioned comorbidities are shown in
Supplementary Table S3. We used the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation
[9] to calculate renal function, and an estimated glom-
erular filtration rate (eGFR) < 30mL/min/1.73 m2 de-
scribed significant renal insufficiency. Patients were
excluded if no creatinine concentrations were available
the same day as or within a week from the index date.
Patients with missing serum sodium measurements on
the index date were also excluded.
Prescriptions redeemed up to 90-days before the
index date were identified for the following drugs: po-
tassium supplements, non-steroidal anti-inflammatory
drugs, corticosteroids, laxatives, xanthines, and anti-
microbials. See Supplementary Table S3 for relevant
ATC codes.
Exposure variable
Serum and plasma measurements yield similar results,
but for serum samples there is a risk of contamination
with potassium from burst platelets during coagulation
in the range of 0.1–0.5 mmol/L due to non-standard
sample handling [10]. Therefore, we only used plasma
potassium measurements.
There is not a consensus on the normal plasma potas-
sium interval, as it can vary from population to popula-
tion. Supplementary Table S4 gives an overview on the
three most used reference intervals in serum and plasma
originating from different populations. We defined hypo-
kalemia as plasma potassium concentrations below 3.5
mmol/L and borderline hypokalemia as potassium levels
within the interval 3.5–3.7 mmol/L. Hyperkalemia was
defined as potassium levels above 4.6 mmol/L. [11] For
K2, seven predefined potassium intervals were
constructed: 1.5–2.9 mmol/L, 3.0–3.4 mmol/L, 3.5–3.7
mmol/L, 3.8–4.0 mmol/L, 4.1–4.6 mmol/L, 4.7–5.0
mmol/L and 5.1–7.1 mmol/L. Plasma potassium interval
K: 3.8–4.0 mmol/L was used as the reference for statis-
tical analyses. We chose this interval as the reference
group because it had one of the largest number of pa-
tients and lowest mortality rate.
Outcome
The primary outcome was all-cause mortality within 60
days from K2. The secondary outcome was presumed
cardiovascular death within 60 days from K2.
Statistical analyses
Categorical variables were presented as counts and per-
centages, and continuous variables as median with corre-
sponding 25th and 75th percentiles. Differences between
variables were compared using chi-squared and Kruskal-
Wallis tests, as appropriate.
To illustrate survival probability, Kaplan Meier curves
were plotted for the seven potassium intervals. A re-
stricted cubic spline curve was constructed to investigate
the relationship between potassium as a continuous vari-
able and absolute mortality risk in an age, sex, comor-
bidity and drug standardized population.
Cox proportional hazard modeling was used to analyze
the association between the seven predefined potassium
intervals and 60-day all-cause and presumed cardiovas-
cular mortality. Based on the Cox regression principle,
we modelled an average effect to estimate the 60-day ab-
solute risk of all-cause mortality, with potassium interval
3.8–4.0 mmol/L as reference.
The multivariable model was adjusted for: age, sex,
serum sodium, renal insufficiency, malignancy, heart fail-
ure, chronic liver disease, chronic obstructive pulmonary
disease, diabetes mellitus, stroke, atrial flutter/fibrilla-
tion, ischemic heart disease, inflammatory bowel disease,
antihypertensive therapy, corticosteroids, antimicrobials,
non-steroidal anti-inflammatory drugs, xanthines, laxa-
tives, and potassium supplements. The proportional
hazard assumption was tested by plotting Schoenfeld re-
siduals and was not violated. Interactions on mortality
were tested by comparing the likelihood ratio of the Cox
regression model with and without the interaction term.
The following variables were tested for interaction with
plasma potassium on mortality: age, sex, and renal insuf-
ficiency. A two-sided p-value < 0.01 was considered
statistically significant for interactions. We found no sta-
tistically significant interactions. For other analyses, a
two-sided p-value < 0.05 was considered statistically sig-
nificant. Linearity of age on mortality was also assessed
through a likelihood ratio test comparing a linear
description with a categorical one. Age was found to
violate linearity and was included as a categorical
variable with five levels, using cut-off values from every
20th percentiles (55, 64, 72, 79 and 101 years). Hazard
ratios (HR) and absolute risks (AR) were estimated with
95% confidence intervals (95% CI). All data management
and analyses were performed using SAS, version 9.4 and
R, version 3.5.0 [12].
Results
Demographics
We identified 8976 patients treated with combination
antihypertensive therapy who had potassium concentra-
tions ≤3.7 mmol/L within the first 100 days from com-
bination therapy initiation. Baseline characteristics for
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the cohort stratified on the seven predefined K2 intervals
are presented in Table 1. Females accounted for 53% of
the total population and median age was 68.3 years
(range 18.2–100.8 years). Of the patients with borderline
hypokalemia at K1, 13% developed hypokalemia and
5.7% hyperkalemia at K2. As for patients with hypokal-
emia at K1, we observed that 28.5% remained hypokal-
emic at the second blood draw and 4.8% developed
hyperkalemia. Approximately half of the population was
hospitalized at K1 and four fifths at K2. See supplemen-
tary Figure S2 displaying the distribution of K1, average
of potassium measurements drawn within 1–5 days from
K1, and K2. A low number of patients (n = 572) had
renal insufficiency at the time of second potassium draw.
Median time from K1 to K2 was 22 days (range: 6–100
days). As for diuretic treatment, thiazides were common
in patients with potassium concentrations ≤3.7 mmol/L,
whereas loop diuretics were more common among pa-
tients with high potassium levels. Thiazide-like diuretics
accounted for 4.4% of the total prescriptions of
thiazides.
Demographics stratified on survival status showed that
age, renal insufficiency, lower sodium concentrations,
hospitalization at the time K1, prior history of malig-
nancy, chronic liver disease, chronic obstructive pul-
monary disease, atrial fibrillation/atrial flutter, heart
failure, and stroke were predominant among the de-
ceased (Supplementary Table S5).
60-day survival after the second potassium measurement
During 60-day follow-up after K2, 627 (7.0%) patients
died, 331 from a cardiovascular cause. Mortality in the
seven strata was: 14.4, 7.0, 6.3, 5.2, 6.7, 13.6 and 21.6%,
respectively. The restricted cubic spline curve revealed a
U-shaped relationship between potassium and mortality
(Fig. 1).
The results of the multivariable Cox regression, with
plasma potassium 3.8–4.0 mmol/L as the reference
group are shown in Fig. 2. All-cause mortality was sig-
nificantly increased in patients with hypokalemia (1.5–
2.9 mmol/L HR 2.39, 95% CI 1.66–3.43 and 3.0–3.4
mmol/L HR 1.36, 95% CI 1.04–1.78) when compared
with the reference. We observed a trend towards
increased mortality in patients with borderline hypokal-
emia and with potassium levels within the interval 4.1–
4.6 mmol/L (HR 1.24, 95% CI 0.97–1.59 and HR 1.20,
95% CI 0.95–1.51, respectively). All-cause mortality was
also elevated in patients with hyperkalemia (4.7–5.0
mmol/L HR 2.36, 95% CI 1.68–3.30; 5.1–5.7 mmol/L HR
2.62, 95% CI 1.73–3.98). The univariable analysis showed
similar results. We observed no interaction between K1
and K2 on 60-day mortality.
Cardiovascular mortality accounted for nearly 53% of
all deaths. We observed increased risk of cardiovascular
death in patients with initial hypokalemia or low normal
potassium levels who had potassium concentrations <
3.0 mmol/L and > 4.6 mmol/L at the second
measurement.
The standardized 60-day absolute risk of all-cause
mortality was lowest in patients with potassium concen-
trations between 3.8–4.0 mmol/L (AR 5.4, 95% CI 4.5–
6.3%, Table 2). Significant differences in risks (reported
against the reference) were observed for the following
potassium intervals: 1.5–2.9 mmol/L risk difference 6.3%
(95% CI 2.9–9.7%); 4.7–5.0 mmol/L risk difference 6.2%
(95% CI 3.2–9.3%); 5.1–7.1 mmol/L risk difference 7.2%
(95% CI 2.8–11.6%).
Subgroup and sensitivity analyses
We performed eleven additional analyses to test the ac-
curacy and robustness of the main results (Table S6).
First, multivariable analysis performed on a subgroup
of patients without kidney insufficiency showed that po-
tassium levels within the intervals 1.5–2.9 mmol/L and
3.0–3.4 mmol/L were associated with increased mortality
risk compared with the reference (3.8–4.0 mmol/L) (HR
2.33, 95% CI 1.56–3.46 and HR 1.35, 95% CI 1.02–1.79,
respectively).
Second, in a subpopulation without history of malig-
nancy, adjusted analyses showed that potassium concen-
trations outside the interval 3.0–4.6 mmol/L were
associated with increased risk of death compared with
the reference.
Third, subgroup analysis on patients without history of
heart failure and no loop diuretic prescription showed
that patients with hypokalemia and hyperkalemia had an
increased mortality risk compared with patients with po-
tassium levels in the interval 3.8–4.0 mmol/L.
Fourth, analysis performed on a subgroup of patients
without ischemic heart disease showed that patients with
severe hypokalemia, and hyperkalemia had increased risk
short-term mortality risk when compared with the
reference.
Fifth, looking at patients with borderline hypokalemia
at the first potassium measurement, we observed that
patients who developed hypokalemia (1.5–2.9 mmol/L:
HR 2.16, 95% CI 1.25–3.73; 3.0–3.4 mmol/L: HR 1.70,
95% CI 1.22–2.37), or hyperkalemia (4.7–5.0 mmol/L:
HR 1.84, 95% CI 1.18–2.86; 5.1–7.1 mmol/L: HR 2.81,
95% CI 1.68–4.71) had an increased risk of death within
60-days when compared with the reference.
Sixth, among patients with hypokalemia at K1, analyses
showed that potassium concentrations within the inter-
vals 1.5–2.9 mmol/L, 4.1–4.6 mmol/L and 4.7–5.0 mmol/
L were associated with increased short-term mortality
risk.
Seventh, by performing the analyses on the last avail-
able potassium measurement within 6–100 days from K1
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instead of the first measurement, we noted that potas-
sium levels below 3.8 mmol/L were associated with in-
creased short-term mortality.
Eighth, analyses on patients with available K2 measure-
ments within 6–45 days from K1, showed that severe
hypokalemia and hyperkalemia were associated with 60-
day all-cause mortality.
Ninth, analyses on patients with available K2 measure-
ments above 45 days from K1, showed that potassium
interval 3.0–3.4 mmol/L was associated with 60-day all-
cause mortality.
Tenth, we stratified K2 in three intervals: 1.5–3.4
mmol/L (hypokalemia), 3.5–4.6 mmol/L (normokalemia)
and 4.7–7.1 mmol/L (hyperkalemia). Mortality within
60-days was increased both in patients with hypokalemia
(HR 1.36, 95% CI 1.12–1.66) and in patients with
hyperkalemia (HR 2.13, 95% CI 1.66–2.74) at K2 meas-
urement compared with patients with normal potassium
concentrations.
Eleventh, multivariable analysis on patients with avail-
able magnesium measurements at the time of plasma
potassium draws, showed significant association of po-
tassium levels below 3.0 mmol/L and mortality (HR 2.46,
95% CI 1.05–5.74). In addition, we also observed a trend
towards increased risk of death in patients with potas-
sium between 3.0–3.4 mmol/L.
Discussion
This Danish register-based cohort study investigated 60-
day mortality among 8976 patients with hypertension
and hypokalemia or low normal potassium in relation to
a subsequent potassium measurement. The major find-
ings were: (1) Persistent hypokalemia following low
potassium was more than twice as frequent as develop-
ment of hyperkalemia. (2) Persistent hypokalemia was
common and associated with increased all-cause and
presumed cardiovascular mortality; (3) Increase in potas-
sium to levels > 4.6 mmol/L in patients with initial hypo-
kalemia or low normal potassium was associated with
increased all-cause and cardiovascular mortality; (4)
Among patients with borderline hypokalemia initially,
development of hypokalemia or hyperkalemia was asso-
ciated with increased mortality risk; (5) Correcting hypo-
kalemia associated with increased survival.
In the current study, we observed significantly higher
60-day mortality risk in patients with potassium
Fig. 1 Age, sex, comorbidity and drug standardized 60-day risk of all-cause death in relation to plasma potassium as a continuous variable. Model
adjusted for age, gender, plasma sodium, renal insufficiency, malignancy, heart failure, chronic liver disease, chronic obstructive pulmonary
disease, diabetes mellitus, atrial flutter/fibrillation, stroke and ischemic heart disease, antihypertensive therapy, corticosteroids, antimicrobials, non-
steroidal anti-inflammatory drugs, potassium supplement, xanthines, laxatives
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concentrations < 3.5 or > 4.6 mmol/L after an episode
with hypokalemia or low normal potassium. This finding
was not surprising as we previously observed an appar-
ent optimal potassium range within 4.1–4.7 mmol/L in a
similar population [5]. Of 8976 patients with initial
plasma potassium ≤3.7 mmol/L, 18% had potassium con-
centrations ≤3.7 mmol/L at the second measurement
and 5.4% > 4.6 mmol/L, suggesting that potassium deficit
is frequently underestimated than overestimated by phy-
sicians. Notably, 13% of the patients with borderline
hypokalemia (K: 3.5 and 3.7 mmol/L) at the first
measurement experienced a further decrease in potas-
sium (< 3.5 mmol/L) at the second measurement. This
suggests that the association of low normal potassium
Fig. 2 All-cause and cardiovascular mortality after hypokalemia or borderline hypokalemia according to subsequent potassium measurements in
patients treated with combination antihypertensive therapy (60-days follow-up, n = 8976). Potassium interval K: 3.8–4.0 mmol/L represented the
reference range. Adjusted for age, gender, serum sodium, renal insufficiency, malignancy, heart failure, chronic liver disease, chronic obstructive
pulmonary disease, diabetes mellitus, atrial flutter/fibrillation, stroke and ischemic heart disease, antihypertensive therapy, corticosteroids,
antimicrobials, non-steroidal anti-inflammatory drugs, potassium supplement, xanthines, laxatives
Table 2 60-day standardized absolute risk for all-cause death after hypokalemia or borderline hypokalemia according to subsequent
potassium measurements in patients treated with combination antihypertensive therapy (n = 8976). Potassium interval K: 3.8–4.0
mmol/L represented the reference range. Adjusted for age, gender, serum sodium, renal insufficiency, malignancy, heart failure,
chronic liver disease, chronic obstructive pulmonary disease, diabetes mellitus, atrial flutter/fibrillation, stroke and ischemic heart
disease, antihypertensive therapy, corticosteroids, antimicrobials, non-steroidal anti-inflammatory drugs, potassium supplement,
xanthines, laxatives
Absolute risk %, (95% CI) 60-d Risk difference %, (95%CI) p-value Average risk ratio %, (95%CI) p-value
P(K) 1.5–2.9 mmol/L 11.7% (8.3–15.0) 6.3 (2.9–9.7) < 0.001 2.17 (1.46–2.88) 0.001
P(K) 3.0–3.4 mmol/L 7.1% (5.8–8.5) 1.7 (0.1–3.4) 0.03 1.32 (0.99–1.66) 0.06
P(K) 3.5–3.7 mmol/L 6.4% (5.3–7.5) 1.0 (− 0.3–2.4) 0.14 1.19 (0.91–1.47) 0.17
P(K) 3.8–4.0 mmol/L 5.4% (4.5–6.3) REF. REF.
P(K) 4.1–4.6 mmol/L 6.3% (5.4–7.2) 0.9 (−0.3–2.2) 0.13 1.18 (0.92–1.44) 0.17
P(K) 4.7–5.0 mmol/L 11.6% (8.7–14.6) 6.2 (3.2–9.3) < 0.001 2.17 (1.51–2.82) < 0.001
P(K) 5.1–7.1 mmol/L 12.6% (8.2–16.9) 7.2 (2.8–11.6) 0.001 2.34 (1.45–3.22) 0.003
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concentrations with mortality that we previously ob-
served [5] can partly be explained by further declines in
potassium levels, and that low normal potassium con-
centrations might be a marker for an ongoing decrease
in potassium.
Our results also suggest that correction of hypokal-
emia is important in relation to short-term mortality, as
patients in the middle of the normal reference interval
had good prognosis. Guidelines recommend supplemen-
tation with potassium when plasma potassium levels are
below 3.5 mmol/L. [13] However, in this study we can-
not elucidate because of the low follow-up time the
mechanism through which patients increased or de-
creased in potassium concentrations. It is also difficult
to state whether potassium is a risk factor or a risk
marker regarding mortality. Our population is relatively
old, patients are treated with at least two antihyperten-
sive drugs, and about 20% of the patients have history of
heart failure, ischemic heart disease, atrial fibrillation/
flutter, chronic obstructive pulmonary disease and dia-
betes. Possibly, potassium concentrations at non-
cardiotoxic levels more likely are a risk marker of great
disease burden, which is very important to recognize
and identify.
Potassium supplementation of asymptomatic patients
with low normal concentrations is controversial. Guide-
lines in the US recommend a stricter standard for potas-
sium replacement therapy (< 4.0 mmol/L) especially in
patients with cardiovascular disease who are at high risk
of ventricular tachyarrhythmias [13]. Our study suggests
that potassium concentrations in the middle of the refer-
ence interval are beneficial even in patients with potas-
sium levels ≤3.7 mmol/L.
Various studies have previously demonstrated that
hypokalemia among patients with cardiovascular disease
is associated with an increased mortality risk [14–18].
However, no prior studies have investigated the impact
of potassium normalization on short-term survival.
Though, one study examined the impact of correcting
hypokalemia within 24 h on the risk of cardiac arrhyth-
mias in hospitalized patients without coronary syn-
dromes or history of arrhythmias [19]. The authors did
not find increased odds of arrhythmia in patients with
hypokalemia whose potassium levels were not corrected
≥3.5 mmol/L. Although, the study does not describe or
account for the cause of admission, comorbidities or
pharmacotherapy. The investigators excluded patients
with history of ischemic heart disease and arrhythmia,
but included patients with heart failure who have a high
arrhythmia risk. Overall, both the study population and
the outcome measure differed in this paper compared
with our study.
Another study performed on 5916 individuals from
the general population found no significant associations
between borderline hypokalemia (3.4–3.6 mmol/L) and
risk of all-cause mortality, risk of stroke or risk of acute
myocardial infarction [20]. Comparing the results of our
study with this study is difficult due to major differences
in study population, methodology and aim. First, our
population was characterized by redemption of at least
two antihypertensive drugs. Mattsson et al. [20] enrolled
participants from the general population, where 49.6%
had high blood pressure at baseline, 13.9% were pre-
scribed heart medication and 10.9% were treated with
diuretics. In our population, we observed higher burden
of cardiovascular disease and use of diuretics. Second,
our aim was to investigate the impact of correcting
hypokalemia or borderline hypokalemia on short-term
all-cause and cardiovascular mortality. In terms of mor-
tality, Mattsson et al. [20] followed participants from
their fourth examination in 2001–2003 until November
2014 or death, having a median follow-up of 11.9 years
(Q1-Q3: 11.4–12.5 years). As potassium is varying over
time especially in patients with cardiovascular disease or
treated with antihypertensive drugs, use of one potas-
sium measurement to assess mortality over more than
10 years can provide results that are difficult to interpret.
Shorter follow-up time or time varying analysis where
the authors accounted for both multiple measurements
over time and change in relevant medication would have
provided better methodology. Although, it is important
to acknowledge that correcting hypokalemia and low
normal potassium might not have the same impact in
general population compared to a population with heart
disease.
Another study investigated the influence of dyskalemia
at admission and early dyskalemia correcting on short-
term survival and cardiac events among intensive care
unit (ICU) patients [21]. The authors concluded that pa-
tients with persisting hypokalemia or hyperkalemia
within the first 2 days in ICU had increased risk of
death. The two populations are not comparable, however
both studies emphasize the importance of rapid correc-
tion of hypokalemia to improve short-term mortality.
Limitations
The limitations are related to the observational nature of
register-based studies, which imply non-causal interpret-
ation of the results.
We did not have information about comorbidities and
risk factors from the primary sector. Therefore, patients
who did not redeem any medication of interest or were
not registered an ICD-code from the secondary sector
could have been misclassified as “healthy”. Patients with
complications related to hypertension have a larger like-
lihood for being referred to the secondary sector and
therefore also a higher probability for being diagnosed
with other conditions (compared with patients with
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uncomplicated hypertension), leading to an ascertain-
ment/surveillance bias and non-differential misclassifica-
tion bias. To reduce this bias, we defined hypertension
as use of at least two antihypertensive drugs in two con-
comitant quarters. Whether hypertension was resistant,
controlled or uncontrolled was unkown, and data about
ejection fraction and type of heart failure was not
available.
We cannot exclude that the blood draws may contain
hemolysis. However, in case of significant hemolysis the
samples submitted are rejected and no potassium value
is available.
We could not investigate the effect of any potential
treatment or drug dosage adjustment in the time be-
tween the first and second potassium measurement. The
Danish National Prescription Registry records filled pre-
scriptions; thus, changes in dosage cannot be identified,
unless a new drug is prescribed. In addition, the majority
of the patients were hospitalized at the time of
potassium measurement and any treatment during
hospitalization is not registered in the Danish National
Prescription Registry. Moreover, it was also difficult to
identify the cause of hypokalemia using the registers.
Hypokalemia might have occurred due to administra-
tion of diuretics, alkalosis, derangements in the renin
angiotensin aldosterone system, gastroenteritis or
other pathologies. However, the purpose of this study
was neither to investigate the cause of hypokalemia,
nor to assess the strategies used to correct low potas-
sium concentrations. The purpose of this study was
to find a clue, whether normalization of potassium
had an effect on short-term mortality, whether we
should increase potassium concentrations in patients
with borderline hypokalemia and whether potassium
actually increased.
It is also important to acknowledge that plasma potas-
sium is not always a good predictor of the whole body
potassium. Yet, it is the most commonly used method to
assess potassium and only in patients with persistent
hypokalemia over a longer period of time total body po-
tassium is calculated.
Conclusion
Persistent hypokalemia was frequent and associated with
increased all-cause and cardiovascular mortality. In-
crease in potassium to levels > 4.6 mmol/L in patients
with initial hypokalemia or low normal potassium was
associated with increased all-cause and cardiovascular
mortality.
Perspectives
We were not able to report the initiatives medical doc-
tors undertook after observing potassium levels below
3.8 mmol/L at the first measurement. However, our
results emphasize the importance of potassium
normalization after an episode with hypokalemia and
low normal potassium and that overcorrection is associ-
ated with an increased risk of death. Potassium concen-
trations in the middle of the normal reference interval
are associated with good prognosis. Possibly, potassium
supplementation, use of mineral receptor antagonists or
thiazide-like diuretics instead of thiazide-type in patients
with potassium concentrations ≤3.7 mmol/L could be of
clinical importance, but requires further study, prefera-
bly through a randomized controlled trial.
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